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Human Cytomegalovirus (CMV) 
 Beta herpesvirus (HHV-5)
 Infects 50-85% of US adults by age 40
 CMV not eliminated after 1° infection
 Remains in latent state within granulocytes, 
macrophages, and dendritic cell precursors
 Asymptomatic in immunocompetent host
 High risk groups
 Hematopoietic stem cell transplant patients 
 Solid organ transplant patients 
 AIDS patients and other immunocompromised patients
 Fetuses of mothers infected during pregnancy
 Current therapies
 Antiviral drugs (e.g., Ganciclovir, Valganciclovir)
 Cytogam®: Pooled human immune globulin
CMV DNA Vaccines
 TransVaxTM CMV therapeutic vaccine
 Phase 2 clinical data in 2010 in CMV-seropositive      
HCT recipients 
 Potential breakthrough in a niche market with the 
potential to expand to SOT
 CyMVectinTM CMV prophylactic vaccine 
 Potential for clinical efficacy data in CMV-seronegative 
women of childbearing potential
 Addresses one of the last large ID markets for vaccines 
TransVax™ CMV Vaccine
Product Description
 Single vial formulation
 Two plasmids: gB + pp65 
(5 mg total DNA in 1 mL dose)
 CRL1005 poloxamer (7.5 mg/mL)
+ Benzalkonium chloride (BAK; 0.11 mg/mL)
 Stable at -30°C for >3 years
 Completed Phase 1 trial
 Successfully dose-escalated up to 5 mg DNA 
dose by IM injection (J Infect Dis 2008)
 Induced T-cell and antibody responses
 Noninfectious
 Orphan drug status for HCT and SOT    
in the U.S.
CMV in Hematopoietic Cell Transplant 
Hypotheses and Assumptions
 Reactivation in ~60% of CMV+ recipients within 100 days 
after transplant; if untreated can cause pneumonitis, 
hepatitis, gastroenteritis, retinitis, leukopenia, encephalitis
 Meyers et al., 1986; Junghanss et al., 2002, 2003
 DNA vaccination should increase CMV-specific T-cell and 
antibody responses
 Selinsky et al., 2005; Hartikka et al., 2008; Wloch et al., 2008
 Increased cellular immune responses should reduce viremia 
(incidence, onset, duration)
 Cwynarski et al., 2001; Aubert et al., 2001, Hakki et al., 2003
 Reduced viremia should decrease antiviral use and CMV 
disease
 Emery et al., 2000
TransVax™ CB01-202 Phase 2 HCT Trial
 Randomized, double-blind, placebo-controlled
 18-65yo CMV+ HCT recipients with leukemia or lymphoma
 6/6 or 5/6 HLA allele match
 Stratified by site, donor CMV status, HLA match
 Randomized 1:1 for active vs. placebo
 Multicenter (16 enrolling U.S. sites)
 Completed enrollment 4Q08
 1 year follow-up after transplant
TransVax™ Phase 2 Trial
Recipient-only Immunization Regimen
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Viral Load and Antiviral Therapy Use
 Viral load monitored by both local and central lab assays
 Weekly (wk 3-13), Biweekly (wk 14-28), Monthly (wk 29-52)
 Central Mayo lab used standardized assay for comparing 
viral loads from all sites    
 Roche LightCycler PCR using polymerase primers
 Different local lab assays and treatment algorithms at each 
site used to determine dose and duration of antiviral therapy
 PCR or antigenemia assays
 Four antivirals used for induction and maintenance Rx
 Ganciclovir, Valganciclovir, Foscarnet or Cidofovir
Interim Analysis Endpoints
 Safety
 Cellular response (pp65 and gB)
 Antibody response (gB)
 Viral load (≥ 500 copies/mL lower limit of detection by PCR)
 Occurrence of CMV infection (any occurrence of ≥ 500 copies/mL)
 Duration of viremia (% of days on study with ≥ 500 copies/mL)
 Viral load Area Under the Curve (total copy numbers for time on study)
 Peak viral load (highest copy number by PCR during study)
Demographic and Baseline Characteristics
TransVaxTM
(N=40)
Placebo
(N=34)
Gender Female
Male
21 (52%)
19 (48%)
12 (35%)
22 (65%)
Race Caucasian
African American
37 (93%)
3 (7%)
31 (91%)
3 (9%)
Age Mean (years) 49.8 49.1
Donor CMV status* Positive
Negative
20 (50%)
20 (50%)
19 (56%)
15 (44%)
HLA Allele Matching* 6/6
5/6
37 (93%)
3 (7%)
32 (94%)
2 (6%)
Relatedness to Donor Related
Unrelated
22 (55%)
18 (45%)
15 (44%)
19 (56%)
Conditioning Regimen Myeloablative
Nonmyeloablative
29 (73%)
11 (27%)
23 (68%)
11 (32%)
* Groups were stratified by site, donor CMV status, and HLA match
Preliminary Safety
 Data Safety Monitoring Board
 DSMB reported „No safety concerns detected‟ for first 
20 patients through Day 56
 Continued review of SAEs and safety reports for 
remainder of study 
 SAEs
 One report of angioedema after second dose, 
possibly related to study drug or metaclopramide
 No other study discontinuations due to related AEs
 No difference between groups in SAEs
TransVax™
(N=40)
Placebo
(N=34)
TransVax™
vs Placebo
Mean number of injections 2.6 2.6 -
Initiation of CMV antiviral Rx 19 (48%) 18 (53%) - 9%
Recurrent use of CMV antiviral Rx 4 (10%) 7 (21%) - 52%
CMV disease 3 (7%) 3 (9%) -
Death 3 (7%) 3 (9%) -
Clinical Observations Up to 4 Months
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Viral Load Endpoints
Up to 4 Months
ND: not detectable
Based on PCR results from central lab (Mayo Clinical Trial Services)
TransVaxTM
(N=40)
Placebo
(N=34)
% Reduction 
vs Placebo
Occurrence of CMV infection
(subjects reaching ≥ 500 copies/mL) 12 (30%) 17 (50%) - 40%
Recurrence of CMV infection
(subjects with 2 or more episodes of ≥ 500 copies/mL) 3 (7%) 7 (21%) - 67%
Duration of viremia
Mean (days)
Mean (percentage)
7.8
7.1
11.9
10.5
-35%
- 32%
AUC viral load (total copies)
Mean
Range
779
83-14,474
1021
198-14,417
- 24%
Peak viral load (copies/mL)
Mean
Median
Range
2575
ND
ND-29,500
8537
1125
ND-145,000
- 70%
↑ ↑ ↑
Time to Initial Viral Reactivation
Up to 4 Months
TransVax™ Phase 2 HCT Trial
Summary of Preliminary Findings
 DNA vaccination was safe and immunogenic in the HCT population
 Apart from an allergic response in one subject, no evidence of unexpected safety 
concerns in this population
 TransVax™ improved cellular responses to pp65 and gB vs. placebo 
 TransVax™ enhanced the level of gB antibodies, once the immune 
system recovered, and these were sustained at one year
 A 4th dose of TransVax™ was safe and augmented the response
 Viral load endpoints at 4 months favored TransVax™ vs. placebo
 Decreased occurrence of CMV infection (detectable viremia by Mayo Clinic PCR)
 Decreased recurrence of CMV infection
 Delayed time to initial detectable viremia
 Decreased duration of viremia
 Decreased AUC & peak viral load
Congenital CMV Infection
Unmet Medical Need
 Most common intrauterine infection in the U.S.
 30%-40% risk if primary infection occurs during pregnancy
 1% of newborns are infected
 Results in death or severe disability in >8,000 infants per year
 Leading infectious cause of sensorineural hearing loss and mental 
retardation
 Every hour another child becomes permanently disabled from congenital 
CMV Infection
 400 infants die each year
 Major priority for vaccine as sanctioned by Institute of Medicine 
 No standard of care therapy
 No licensed vaccine or late-stage vaccines in development
CyMVectinTM CMV Vaccine
Product Concept 
Vaxfectin®-formulated gB +/- pp65 pDNA vaccine
 Antibodies to gB are the predominant correlate of protection   
for CMV infection
 gB protein vaccine reduced maternal infection (Pass, NEJM 2009)
 pp65 alone can reduce maternal viral load in guinea pig model
 Strong gB antibody responses induced in animal models
 Phase 1 trials of Vaxfectin®-formulated DNA vaccine  
completed (H5N1 influenza)
 Well-tolerated safety profile
 Antibody and T-cell responses achieved with only 2 doses
 H5 considered to be poor-to-modest immunogen
 3 IM injections of Vaxfectin®-formulated CMV DNA vaccine to be tested 
with regimen similar to Gardasil®
Vaxfectin® Adjuvant
Cationic Lipid
Co-Lipid
GAP-DMORIE
1,2-diphytanoyl-sn-glycero-3-
phosphoethanolamine
DPyPE
(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-
tetradeceneyloxy)-1-propanaminium bromide
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Vaxfectin® Profile
• Two-lipid mixture
• Forms microparticles
• Increases immune responses  
and protection in animal models
• Dose sparing
• Scaleable cGMP manufacturing
• Simple formulation
• Patented technology
Vaxfectin®-formulated CMV DNA Vaccine 
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NZW rabbits (n=6 per group) injected with 100 µg gB DNA (PBS or Vaxfectin® formulation)   
by single IM (vastus lateralis) or ID injection with needle or Biojector®2000 on Days 0 and 21
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Immune Responses to Vaxfectin®-
formulated DNA vs Electroporation
 IM or ID delivery of Vaxfectin®-formulated pDNA CMV vaccine resulted in anti-gB titers 
similar to those obtained with EP-assisted delivery (historical study)
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Biodistribution of Vaxfectin®-formulated 
DNA Vaccine in Rabbits
Bilateral  IM injection of 0.5 mg DNA/muscle [~28X human dose (mg/kg)]; 5 rabbits/sex/timepoint; 
tissues analyzed at Day 29 a and Day 61 b
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Summary of Phase 1 Vaxfectin®-
formulated DNA Vaccine (H5N1)
Safety
 All vaccine doses were well tolerated
 No discontinuations due to vaccination/adverse events
 Adverse events typically resolved in a few days
 No vaccine-related clinical or laboratory serious adverse events
 Most common reactions:  Injection site pain, headache, malaise, myalgia
Immune responses
Monovalent cohorts:
 HI antibody response rates from 47%-67%
 Peak titers by day 56, sustained titers to day 182 in 33%-50%
 HI antibody responses in the reported range of protein-based vaccines
 H5 T-cell responses in 75%-100% sustained for at least 6 months
CyMVectinTM
Proof-of-Concept Clinical Trial
 IND allowed by the FDA
 A Phase 1 trial in CMV seronegative women with a child 
in day care center
 CMV infection rate in women of childbearing age > 20% if child   
in day care center 
 Immunization schedule: 0, 1 and 6 months
 Endpoints
 Immunogenicity 
 Safety
 Occurrence rate of, and time to CMV infection
 Clinical “proof of concept” with approximately 80 subjects
 Randomized 1:1 for active vs. placebo
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